secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kyverna Therapeutics, Inc. (KYTX)
CIK:        0001994702
Form:       8-K
Filed at:   2025-10-29T23:59:59+00:00
Accession:  0001193125-25-254698
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kyverna reports positive interim Phase 2 data for KYV-101 in generalized myasthenia gravis
--------------------------------------------------------------------------------

- Positive interim data from Phase 2 portion of KYSA-6 trial of KYV-101 announced on October 29, 2025.
- Conference call held same day at 8 a.m. Eastern Time to discuss results; slides furnished as Exhibit 99.1.
- No specific efficacy or safety figures included in the filing text; detailed data in attached slide deck.
- Kyverna is a clinical-stage biotech focused on CAR T-cell therapies for autoimmune diseases.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1994702/000119312525254698/0001193125-25-254698-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1994702/000119312525254698/d59631d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-254698

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer